{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:53:52Z","timestamp":1789736032514,"version":"4.0.1"},"reference-count":44,"publisher":"BMJ","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gut"],"accepted":{"date-parts":[[2010,5,18]]},"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The aim of this study was to explore the association of serum fibrosis marker levels with the risk of clinical and histological disease progression in a large cohort of patients with chronic hepatitis C (CHC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>462 prior non-responders to peginterferon and ribavirin enrolled in the randomised phase of the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial had baseline and annual serum samples tested for hyaluronic acid (HA), N-terminal peptide of procollagen type 3, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) and YKL-40. All patients underwent a pretreatment liver biopsy and follow-up biopsies at years 2 and 4. Histological progression was defined as a \u22652 point increase in Ishak fibrosis score in patients without cirrhosis. Clinical outcomes included development of decompensation, hepatocellular cancer, death or an increase in the CTP (Child\u2013Turcotte\u2013Pugh) score to \u22657.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean patient age was 49.5\u2005years and 39% had histological cirrhosis at entry. Baseline HA, YKL-40 and TIMP-1 levels combined with other laboratory parameters were all significantly associated with clinical outcomes in the 69 (15%) patients with disease progression (p&lt;0.0001). The best multivariate model to predict clinical outcomes included baseline bilirubin, albumin, international normalised ratio (INR) and YKL-40 levels. All of the baseline serum fibrosis marker levels were also significantly associated with histological fibrosis progression that developed in 70 (33%) of the 209 patients with cirrhosis (p &lt;0.0001). However, baseline HA and platelet counts were best at predicting histological progression (area under the curve (AUC)=0.663).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pretreatment serum fibrosis marker levels are significantly increased in patients with CHC at risk of clinical and histological disease progression. If validated in additional cohorts, measurement of these markers could help identify patients with CHC who would benefit from more frequent and intensive monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration Number<\/jats:title>\n                    <jats:p>NCT00006164.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gut.2010.207423","type":"journal-article","created":{"date-parts":[[2010,7,31]],"date-time":"2010-07-31T20:15:10Z","timestamp":1280607310000},"page":"1401-1409","source":"Crossref","is-referenced-by-count":84,"title":["Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C"],"prefix":"10.1136","volume":"59","author":[{"given":"Robert J","family":"Fontana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jules L","family":"Dienstag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert L","family":"Bonkovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K","family":"Sterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Naishadham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary D","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna S F","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace L","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the HALT-C Trial Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2010,7,30]]},"reference":[{"key":"2025121303052601000_59.10.1401.1","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2003.50073"},{"key":"2025121303052601000_59.10.1401.2","first-page":"777","article-title":"Changing trends in hepatitis C-related mortality in the United States, 1995\u20132004","volume":"31","author":"Wise","year":"2008","journal-title":"Hepatology"},{"key":"2025121303052601000_59.10.1401.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"2025121303052601000_59.10.1401.4","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-5-200403020-00010"},{"key":"2025121303052601000_59.10.1401.5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510230607"},{"key":"2025121303052601000_59.10.1401.6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22759"},{"key":"2025121303052601000_59.10.1401.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.hep.2003.09.022"},{"key":"2025121303052601000_59.10.1401.8","first-page":"1945","article-title":"Sampling error and interobserver variability in liver biopsy in patients with chronic HCV infection","volume":"15","author":"Regev","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"2025121303052601000_59.10.1401.9","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"2025121303052601000_59.10.1401.10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22099"},{"key":"2025121303052601000_59.10.1401.11","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2036.2007.03252.x","article-title":"Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation","volume":"25","author":"Poynard","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121303052601000_59.10.1401.12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21695"},{"key":"2025121303052601000_59.10.1401.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.02.008"},{"key":"2025121303052601000_59.10.1401.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70402-6"},{"key":"2025121303052601000_59.10.1401.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00110-6"},{"key":"2025121303052601000_59.10.1401.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.10.016"},{"key":"2025121303052601000_59.10.1401.17","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(08)60005-7","article-title":"Colchicine versus peginterferon alfa-2b long term therapy: results of the 4 year CoPilot Trial","volume":"48","author":"Afdhal","year":"2008","journal-title":"J Hepatol"},{"key":"2025121303052601000_59.10.1401.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707615"},{"key":"2025121303052601000_59.10.1401.19","doi-asserted-by":"crossref","unstructured":"Bruix J Poynard T Colombo M . Final results of the EPIC3 cirrhosis maintenance trial: pegintron maintenance therapy in cirrhotic (METAVIR F4) HCV patients, who failed to respond to interferon\/ ribavirin (IR) therapy [Abstract]. Gastroenterology 2009;136:A#295.","DOI":"10.1016\/S0016-5085(09)63680-5"},{"key":"2025121303052601000_59.10.1401.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.10.034"},{"key":"2025121303052601000_59.10.1401.21","first-page":"690","article-title":"Chronic hepatitis: morphology and nomenclature","volume":"7","author":"Ishak","year":"1994","journal-title":"Mod Pathol"},{"key":"2025121303052601000_59.10.1401.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.11.002"},{"key":"2025121303052601000_59.10.1401.23","unstructured":"Burnham KP Anderson DR . Model selection and multi-model inference: a practical\u2013theoretical approach. 2nd edn. New York: Springer-Verlag, 2002:20\u201330."},{"key":"2025121303052601000_59.10.1401.24","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.08.052"},{"key":"2025121303052601000_59.10.1401.25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01761.x"},{"key":"2025121303052601000_59.10.1401.26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22517"},{"key":"2025121303052601000_59.10.1401.27","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2006.070961"},{"key":"2025121303052601000_59.10.1401.28","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510240106"},{"key":"2025121303052601000_59.10.1401.29","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3748\/wjg.v11.i4.476","article-title":"Non-invasive estimation of liver fibrosis and response to interferon therapy by as serum fibrogenesis marker, YKL-40, in patients with HCV associated disease","volume":"11","author":"Saitou","year":"2005","journal-title":"World J Gastroenterol"},{"key":"2025121303052601000_59.10.1401.30","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21117"},{"key":"2025121303052601000_59.10.1401.31","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v112.pm9024300"},{"key":"2025121303052601000_59.10.1401.32","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21176"},{"key":"2025121303052601000_59.10.1401.33","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.09.007"},{"key":"2025121303052601000_59.10.1401.34","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22311"},{"key":"2025121303052601000_59.10.1401.35","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.050302"},{"key":"2025121303052601000_59.10.1401.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00184-3"},{"key":"2025121303052601000_59.10.1401.37","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20020075"},{"key":"2025121303052601000_59.10.1401.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80095-1"},{"key":"2025121303052601000_59.10.1401.39","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21508"},{"key":"2025121303052601000_59.10.1401.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.09.016"},{"key":"2025121303052601000_59.10.1401.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80314-1"},{"key":"2025121303052601000_59.10.1401.42","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/jhep.2002.36128","article-title":"Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model","volume":"36","author":"Forns","year":"2002","journal-title":"Hepatology"},{"key":"2025121303052601000_59.10.1401.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.02.021"},{"key":"2025121303052601000_59.10.1401.44","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2003.02930.x"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gut.2010.207423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T11:05:35Z","timestamp":1765623935000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gut.2010.207423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,30]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2010,9,10]]},"published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1136\/gut.2010.207423"],"URL":"https:\/\/doi.org\/10.1136\/gut.2010.207423","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.7276957.7525055","asserted-by":"object"}]},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,30]]}}}